ZEISS MyoCare Spectacle Lenses Show Strong Myopia Control Across Asia and Europe

ZEISS MyoCare (CARE) – Clinical Evaluation of MyoCare in Europe (CEME) Study

1. Study Design & Scope

• A prospective, multicenter, double-masked, randomized clinical trial conducted across Asia (China) and Europe.

• European cohort (CEME Study):

  • Enrolled around 234–304 Caucasian children aged 6–13 years.

  • Eligibility: cycloplegic spherical equivalent (SE) between –0.75 D and –5.00 D, with past annual progression of at least –0.50 D.

• Treatment group wore ZEISS MyoCare spectacle lenses with cylindrical annular refractive elements; control group wore single-vision lenses (SVL).

2. Efficacy Results: Refractive Error & Axial Length

Asian Children (2-Year Data)

• After 24 months:

  • Myopia progression slowed by 0.44 D compared to SVL.

  • Axial length (AL) elongation reduced by 0.20 mm.

• Variant MyoCare S:

  • Slowed progression by 0.41 D and AL by 0.17 mm.

Caucasian (European) Children (1-Year Data)

• After 12 months:

  • Myopia progression slowed by 0.21 D.

  • AL growth reduced by 0.14 mm.

  • Significant reduction in “fast progression” cases (progression ≥ 0.50 D or AL ≥ 0.20 mm).

• ZEISS MyoCare showed consistent benefit regardless of prior progression history.

3. Tolerability & Adaptation

• Rapid adaptation observed: 84% of lens wearers adapted within 3 days in Europe.

• Visual performance ratings:

  • 95% rated distance vision as “good or very good”.

  • 93% rated near vision positively.

  • 96% reported good vision during sports and daily activities.

4. Visual Acuity & Subjective Comfort

• At dispensing:

  • Central visual acuity was slightly better with MyoCare than SVL (not clinically significant).

  • Peripheral visual acuity was about one line lower with MyoCare.

• At 3 months:

  • Central vision and subjective adaptation scores matched SVL.

  • Peripheral vision reduction persisted but remained within acceptable clinical limits.

• Adaptation scores improved over time, showing equivalence to SVL by 3 months for most parameters.

Summary Table: Key Findings

Why These Findings Matter

• Cross-population efficacy: ZEISS MyoCare demonstrated consistent benefits across Asian and European children, proving applicability across diverse ethnic groups.

• High compliance potential: Rapid adaptation and strong subjective satisfaction indicate high likelihood of long-term daily wear.

• Clinically acceptable trade-offs: Slight reductions in peripheral vision were observed, but overall visual acuity and comfort matched single-vision standards within a few months.